Filing Analysis
Fennec Pharmaceuticals Inc. reported the results of its annual meeting of shareholders held on June 10, 2026. All proposed resolutions were approved, including the election of five directors and the appointment of Haskell & White LLP as the independent public accounting firm.
📋 Key Facts
- Annual meeting of shareholders held on June 10, 2026.
- Five directors elected: Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, and Jeffrey Hackman.
- Haskell & White LLP appointed as the independent public accounting firm.
- Executive compensation advisory vote approved.
- Amendments to the 2020 Equity Incentive Plan and the adoption of the 2026 Equity Inducement Plan were approved.
Fennec Pharmaceuticals announced that new research evaluating its drug PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
🚩 Red Flags
- Minor clerical inconsistency: The section is labeled 'Item 8.01. Other Events' but the text refers to 'The information contained in this Item 7.01' in its disclaimer paragraph.
📋 Key Facts
- The announcement was made on May 21, 2026.
- The research evaluates PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types.
- The data will be shared as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program.
- A copy of the press release was furnished as Exhibit 99.1.
Fennec Pharmaceuticals granted 50,000 stock options to three new employees as inducement awards under its 2026 Equity Inducement Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and carry an exercise price of $9.75.
📋 Key Facts
- Grant date of May 18, 2026, for 50,000 common shares.
- Options awarded to three new employees as inducement to join the company.
- Exercise price is $9.75 per share with a ten-year term.
- Vesting schedule: one-third on the first anniversary, followed by monthly vesting over the subsequent 24 months.
Rostislav Raykov has notified Fennec Pharmaceuticals of his intention to retire from the Board of Directors and will not stand for re-election at the 2026 Annual Meeting. Following his departure, the Board will reduce its size from six to five directors.
📋 Key Facts
- Director Rostislav Raykov notified the company of his retirement on April 27, 2026.
- Raykov will not stand for re-election at the 2026 annual meeting of shareholders.
- The Board of Directors determined to reduce the board size from six to five directors effective after the meeting.
- The company explicitly stated the departure was not due to any disagreement regarding operations, policies, or practices.
Fennec Pharmaceuticals announced that four abstracts evaluating its drug PEDMARK (sodium thiosulfate injection) have been accepted for presentation or publication at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
📋 Key Facts
- Four abstracts related to PEDMARK were accepted for the 2026 ASCO Annual Meeting in Chicago.
- PEDMARK (sodium thiosulfate injection) is the company's primary product under evaluation.
- The press release announcing these presentations was issued on April 21, 2026.
- The information was filed under Item 8.01 (Other Events) of Form 8-K.
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by the University of Arizona Cancer Center to evaluate PEDMARK® in adult and young adult patients. The study focuses on patients with head and neck and testicular cancers receiving cisplatin treatment.
📋 Key Facts
- Initiation of investigator-sponsored study announced on April 7, 2026.
- Study conducted by University of Arizona Cancer Center.
- Evaluating PEDMARK® (sodium thiosulfate injection) for head and neck and testicular cancers.
- Targeting adolescent, young adult, and adult patients receiving cisplatin.
Fennec Pharmaceuticals Inc. reported its fourth quarter and full year 2025 financial results on March 24, 2026. The filing serves as a standard disclosure of the company's operational performance for the period ended December 31, 2025.
📋 Key Facts
- The report was filed on March 24, 2026, covering the fiscal period ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- A press release detailing the financial results was included as Exhibit 99.1.
- The information is being furnished and not 'filed' for purposes of Section 18 of the Exchange Act.
Fennec Pharmaceuticals has settled its patent litigation with Cipla regarding a generic version of PEDMARK (sodium thiosulfate injection). The agreement prevents Cipla from entering the U.S. market with a generic version until September 1, 2033.
📋 Key Facts
- Settlement agreement reached on March 16, 2026, with Cipla Limited and Cipla USA, Inc.
- Resolves litigation captioned Fennec Pharmaceuticals Inc. v. Cipla Limited and Cipla USA, Inc., C.A. No. 2:23-cv-00123-JKS-MAH.
- Cipla is prohibited from launching its generic sodium thiosulfate product in the U.S. until September 1, 2033.
- The lawsuit will be dismissed with each party bearing its own costs.
- The entry date is subject to earlier entry under certain unspecified circumstances.
Fennec Pharmaceuticals announced that Tampa General Hospital Cancer Institute is initiating a study to evaluate the real-world clinical utility of PEDMARK (sodium thiosulfate injection). The study focuses on reducing the risk of hearing loss (ototoxicity) in adult and young adult cancer patients receiving cisplatin-based chemotherapy.
📋 Key Facts
- Announcement date: March 4, 2026.
- Study partner: Tampa General Hospital Cancer Institute.
- Product: PEDMARK (sodium thiosulfate injection).
- Target population: Adolescent, young adult, and adult cancer patients.
- Clinical focus: Reducing ototoxicity associated with cisplatin-based chemotherapy.
Fennec Pharmaceuticals disclosed real-world data supporting the potential use of PEDMARK® (sodium thiosulfate injection) in adults with head and neck cancers, presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium on February 19–21, 2026. The data from a small retrospective review of 15 adult patients showed the drug was feasible and well tolerated when administered at least six hours after cisplatin, with no disruption to treatment delivery.
🚩 Red Flags
- Very small sample size (n=15) and retrospective design limits the clinical significance of the data
- Adult indication is not yet established — no pivotal trial data or regulatory pathway disclosed
- Information was 'furnished' not 'filed,' indicating the company does not want this data subject to Section 18 liability
📋 Key Facts
- Real-world data from retrospective review of 15 adult patients with head and neck cancers presented at 2026 Multidisciplinary Head and Neck Cancers Symposium (Feb 19–21, 2026)
- PEDMARK® administered at least 6 hours after cisplatin was feasible and well tolerated with no disruption to cisplatin-based treatment delivery
- PEDMARK® is currently FDA-approved only for pediatric patients (1 month of age and older) with localized, non-metastatic solid tumors to reduce ototoxicity risk from cisplatin
- Safety and efficacy of PEDMARK® in adults with head and neck cancers have NOT been established
- Filed as Item 8.01 (Other Events) — information is 'furnished' not 'filed,' meaning it is not incorporated by reference into other SEC filings
- Signed by CFO Robert Andrade; company is incorporated in British Columbia, Canada with principal offices in Research Triangle Park, NC
Fennec Pharmaceuticals announced the initiation of an investigator-sponsored Phase I clinical study conducted by City of Hope. The study aims to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in adult men with metastatic testicular germ cell tumors.
📋 Key Facts
- Initiation of a Phase I investigator-sponsored study (IST) at City of Hope, Duarte, CA.
- Study Identifier: NCT07218913.
- Objective: Evaluate PEDMARK to reduce cisplatin-induced ear damage in men with stage II-III metastatic testicular germ cell tumors.
- PEDMARK is already FDA approved for pediatric patients (one month and older) with localized, non-metastatic solid tumors.
- The drug has a Category 2A recommendation from the NCCN for adolescent/young adult patients.
- Additional investigator-initiated studies are currently under review or in advanced contracting stages.
Fennec Pharmaceuticals announced positive topline results from a Phase 2/3 investigator-initiated clinical trial for PEDMARK in Japan. The study evaluated the drug's ability to reduce cisplatin-induced ototoxicity in pediatric and adolescent patients with non-metastatic solid tumors.
📋 Key Facts
- Announced positive topline results from Phase 2/3 STS-J01 clinical trial.
- Trial focused on PEDMARK (sodium thiosulfate injection) for reducing cisplatin-induced ototoxicity.
- Target population: Pediatric and adolescent/young adult (AYA) patients with non-metastatic solid tumors in Japan.
- PEDMARK is the only FDA-approved therapy indicated to reduce ototoxicity risk associated with cisplatin treatment in pediatric patients 1 month of age and older.
Fennec Pharmaceuticals Inc. has fully redeemed its remaining $30 million senior secured convertible notes issued to Petrichor Opportunities Fund I LP. The redemption, completed on November 17, 2025, satisfies all outstanding payment obligations under the original August 2022 agreement.
🚩 Red Flags
- Significant cash outflow: The company spent over $21.7 million to settle debt, which may impact liquidity depending on the source of funds.
- Redemption fee: A substantial redemption fee of nearly $1.95 million was paid to satisfy the agreement.
📋 Key Facts
- The Company redeemed the remaining Notes in full for an aggregate price of $21,729,455.30 on November 17, 2025.
- Redemption components included $19,476,655.48 in principal/PIK interest, $305,134.27 in accrued interest, and a $1,947,665.55 redemption fee.
- The redemption price was calculated at 110% of the aggregate outstanding principal plus accrued unpaid interest.
- This follows a previous partial redemption of $13,000,000 in December 2024.
Fennec Pharmaceuticals Inc. completed a common share subscription offering of 670,000 shares at $7.50 per share, raising approximately $5.025 million in gross proceeds. The primary purpose of the funds is to repurchase and redeem outstanding convertible notes totaling ~$21.73 million.
🚩 Red Flags
- Significant mismatch between funds raised ($5.0M) and debt to be redeemed ($21.7M), suggesting the offering only covers a fraction of the note obligation or requires additional financing.
- High reliance on existing institutional shareholders for capital injection.
📋 Key Facts
- Offered 670,000 common shares at a price of US$7.50 per share.
- Total gross proceeds from the offering: US$5,025,000.
- Closing date for the offering was November 18, 2025.
- Proceeds are primarily intended to repurchase and redeem 'Petrichor Notes' (convertible notes) issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP.
- The redemption price for the notes is approximately US$21,729,455.
- Remaining net proceeds are earmarked for working capital and general corporate purposes.
Fennec Pharmaceuticals Inc. entered into an underwriting agreement to conduct a public offering of 4,666,667 common shares at $7.50 per share. The offering is expected to close on November 17, 2025.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 4.6 million new shares.
- The offering is being conducted via a shelf registration (S-3), which is common for micro-cap companies needing immediate liquidity.
📋 Key Facts
- Aggregate number of shares to be issued: 4,666,667 common shares.
- Public offering price: $7.50 per share.
- Underwriter purchase price: $6.975 per share.
- Underwriters include Piper Sandler & Co. and Craig-Hallum Capital Group LLC.
- Includes a 30-day option for underwriters to purchase up to an additional 700,000 shares.
- The offering is being conducted under an existing S-3 shelf registration statement (No. 333-275452).
- Expected closing date: November 17, 2025.
Fennec Pharmaceuticals Inc. held its annual meeting of shareholders on June 3, 2025, where all proposed items were approved by shareholders.
📋 Key Facts
- Annual meeting held on June 3, 2025.
- Six nominees (Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, Rostislav Raykov, and Jeffrey Hackman) were elected to the Board of Directors.
- Shareholders approved the appointment of Haskell & White LLP as the independent public accounting firm.
- Shareholders approved an advisory vote on executive compensation.
- Shareholders approved a proposed amendment to the 2020 Equity Incentive Plan.
Fennec Pharmaceuticals Inc. filed an 8-K to announce its full year and fourth quarter financial results for the period ending December 31, 2024.
📋 Key Facts
- Report date: March 10, 2025
- Reporting period: Full year and Q4 ended December 31, 2024
- The filing is primarily a placeholder for the press release containing financial results (Exhibit 99.1).
Fennec Pharmaceuticals announced that its partner, Norgine Pharmaceuticals Ltd., has commercially launched PEDMARQSI (sodium thiosulfate injection) in Germany. This represents a significant commercial milestone for the company's product pipeline in the European market.
📋 Key Facts
- Norgine Pharmaceuticals Ltd. has officially launched PEDMARQSI in Germany.
- PEDMARQSI is identified as sodium thiosulfate injection.
- The announcement was made via a news release on February 7, 2025.
Fennec Pharmaceuticals announced that Norgine Pharmaceuticals Ltd. received positive final draft guidance from NICE recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in pediatric patients.
📋 Key Facts
- Norgine Pharmaceuticals Ltd. received positive final draft guidance from NICE regarding PEDMARQSI.
- The recommendation covers the prevention of cisplatin-induced hearing loss.
- Target patient population: aged 1 month to 17 years with localized, non-metastatic, solid tumors.
Fennec Pharmaceuticals Inc. has entered into a Waiver and Redemption Agreement with Petrichor Opportunities Fund I LP to repurchase $13 million in senior secured convertible notes. This action fully redeems the First and Third Closing Notes, leaving approximately $19.2 million in Second Closing Notes outstanding.
🚩 Red Flags
- Significant reduction in total debt via redemption suggests a major use of cash or equity to settle obligations.
📋 Key Facts
- Redemption amount: $13,000,000 total ($11.8M principal + $1.2M PIK interest).
- The redemption fully settles the First Closing Notes (Aug 2022) and Third Closing Notes (Dec 2023).
- Remaining debt: Approximately $19.2 million in Second Closing Notes remains outstanding as of Dec 19, 2024.
- Agreement date: December 18, 2024.
Fennec Pharmaceuticals Inc. announced the appointment of three new executive officers: Dr. Pierre Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer, effective October 28, 2024.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Dr. Pierre Sayad appointed as CMO; base salary $450,000 + 40% target bonus; 150,000 stock options granted.
- Mr. Terry Evans appointed as CCO; base salary $400,000 + 40% target bonus; 150,000 stock options granted.
- Ms. Christiana Cioffi appointed as CSO; base salary $375,000 + 40% target bonus; 150,000 stock options granted.
- All three executives entered into 'at-will' employment agreements with a 9-month severance provision if terminated without cause.
- Appointments became effective on October 28, 2024.
Fennec Pharmaceuticals Inc. announced a leadership transition on August 5, 2024, involving the departure of long-time CEO Rostislav Raykov and the appointment of Jeffrey S. Hackman as the new CEO.
🚩 Red Flags
- Departure of a long-tenured CEO (15 years) can indicate strategic shifts or internal friction, though he remains on the Board.
- Accelerated vesting of significant option quantities ($7.50 strike price) for the departing CEO.
📋 Key Facts
- Rostislav Raykov is stepping down as CEO after 15 years but will remain on the Board of Directors.
- Jeffrey S. Hackman, a commercial leader with 30+ years of experience in oncology and product launches, has been appointed CEO.
- The Company entered into a Confidential Separation Agreement with Mr. Raykov, including accelerated vesting of up to 292,359 options at $7.50/share.
- Mr. Hackman's compensation includes an annual base salary of $550,000 and a target performance bonus of 50% of his base salary.
- Mr. Hackman was granted 400,000 options subject to a three-year vesting schedule.
Fennec Pharmaceuticals Inc. announced the departure of its Chief Operating Officer, Adrian Haigh, effective June 30, 2024. The company entered into a confidential separation agreement that includes accelerated vesting of certain stock options.
🚩 Red Flags
- Departure of a key executive (COO) who had long-term tenure with the company (9 years as director).
📋 Key Facts
- Adrian Haigh departed as COO on June 30, 2024.
- Mr. Haigh previously served as an independent director for nine years before becoming COO in August 2023.
- A Confidential Separation Agreement was entered into between the Company, its subsidiary Fennec Pharmaceutics (EU) Limited, and Mr. Haigh.
- The agreement includes accelerated vesting of options to purchase up to 66,667 common shares.
- The accelerated options have an exercise price of $8.03 per share and expire on June 30, 2027.
Fennec Pharmaceuticals Inc. held its annual meeting of shareholders on June 25, 2024. Shareholders approved all proposals, including the election of five directors and the appointment of Haskell & White LLP as the independent public accounting firm.
📋 Key Facts
- Annual meeting held on June 25, 2024.
- Five nominees elected to the Board: Dr. Khalid Islam, Chris A. Rallis, Marco Brughera, Jodi Cook, and Rostislav Raykov.
- Haskell & White LLP was appointed as the independent public accounting firm via shareholder vote.
- Shareholders approved an advisory vote on executive compensation.
Fennec Pharmaceuticals Inc. announced the upcoming release of its first quarter 2024 financial results and a corresponding management conference call scheduled for May 14, 2024.
📋 Key Facts
- Q1 2024 financial results to be released before market open on Tuesday, May 14, 2024.
- Management will host a conference call and webcast on May 14, 2024, to discuss business and financial results.
- The filing is an announcement of upcoming earnings rather than the disclosure of actual results.
Fennec Pharmaceuticals Inc. filed an 8-K to announce its full year and fourth quarter financial results for the period ending December 31, 2023.
📋 Key Facts
- Report date: March 21, 2024
- Filing date: March 25, 2024
- Reporting period: Full year and Q4 ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Fennec Pharmaceuticals entered into a significant License and Supply Agreement with Norgine Pharma UK Limited for the exclusive commercialization of PEDMARQSI® in several international territories. The deal includes a substantial upfront payment and potential milestone payments totaling hundreds of millions of euros.
🚩 Red Flags
- Royalty rates are subject to material reduction if generic versions become available in any jurisdiction within the territory.
📋 Key Facts
- Entered into an exclusive license agreement with Norgine Pharma UK Limited on March 15, 2024.
- Territory includes European Economic Area, Switzerland, United Kingdom, Australia, and New Zealand.
- Upfront payment of €40 million was paid to Fennec on March 15, 2024.
- Potential milestone payments up to €210 million based on regulatory and commercial achievements.
- Tiered royalty payments ranging from mid-teen% to mid-twenty% of net sales in the Territory.
- Agreement term lasts for at least until March 2034 or expiration of market exclusivity/patents.
Fennec Pharmaceuticals filed an 8-K/A to amend and restate its previous February 29, 2024, filing. The amendment is intended to properly disclose the results of operations and financial condition for the period ending December 31, 2023.
🚩 Red Flags
- Restatement of previous earnings release/financial disclosure (Item 2.02 amendment).
📋 Key Facts
- Filing is an Amendment No. 1 (8-K/A) to a report filed on February 29, 2024.
- The purpose of the amendment is to properly disclose financial results for Q4 and full-year ended December 31, 2023.
- The original filing was missing certain financial statements, related footnotes, and other financial information required for the Annual Report on Form 10-K.
Fennec Pharmaceuticals Inc. issued a news release providing preliminary unaudited information and management estimates for the fourth quarter of 2023. The results are subject to final year-end audit procedures.
📋 Key Facts
- Report date: February 29, 2024
- Content: Preliminary unaudited Q4 2023 information and management estimates
- Status: Results are subject to completion of financial closing and year-end audit
- Exhibit 99.1 contains the full press release details
Fennec Pharmaceuticals issued a news release regarding an FDA public reminder concerning its product PEDMARK. The FDA is clarifying that PEDMARK is not substitutable with other sodium thiosulfate products.
📋 Key Facts
- FDA issued a public reminder to healthcare providers on February 1, 2024.
- The reminder specifies that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products.
- PEDMARK is the first and only FDA-approved therapy indicated to reduce the risk of cisplatin-associated ototoxicity in pediatric patients.